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Background: The task force on Acute Circulatory Failure of the
Scandinavian Society of Anaesthesiology and Intensive Care Medi-
cine produced this guideline with recommendations concerning the
use of crystalloid vs. colloid solutions in adult critically ill patients
with acute circulatory failure.
Methods: Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) methodology was used to grade the
quality of evidence and to determine the strengths of the recommen-
dations. As efficacy and harm may vary in different subpopulations
of patients with acute circulatory failure, we produced recommen-
dations for general intensive care unit (ICU) patients and those with
sepsis, trauma and burn injury.
Results: For general ICU patients and those with sepsis, we rec-
ommend using crystalloids for resuscitation rather than hydroxy-
ethyl starch and we suggest using crystalloids rather than gelatin
and albumin. For patients with trauma we recommend to use crys-
talloids for resuscitation rather than colloid solutions. For patients
with burn injury we provide no recommendations as there are very
limited data from randomised trials on fluid resuscitation in this
patient population.
Conclusions: We recommend using crystalloid solutions rather
than colloid solutions for resuscitation in the majority of critically ill
patients with acute circulatory failure.
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Practice Guidelines:
• There are other guidelines on fluid therapy for critically ill patients, e.g. from the European Society
of Intensive Care Medicine.
• This guideline was developed in line with new standards and systems for trustworthy guidelines
by the Clinical Practice Committee of the Scandinavian Society of Anaesthesiology and Intensive
Care Medicine to facilitate evidence-based fluid therapy for patients with acute circulatory failure.
• This guideline differs from the previous ones on fluid therapy because it includes recommendations
based on the recently updated systematic reviews and meta-analyses of high-quality trials comparing
crystalloids with colloids.
• Recommendations based on a higher quality of evidence can be given because substantial amounts
of high-quality data have been published in the last years.
[Correction added on 28 January 2015, after first online publication: The Practice Guidelines were
added].
As part of the Scandinavian Society of Anaesthe-
siology and Intensive Care Medicine’s (SSAI)
efforts to improve perioperative and intensive
care, this clinical practice guideline was produced
by the SSAI Acute Circulatory Failure task force.
The work was initiated by the Clinical Practice
Committee of SSAI.
Acute circulatory failure or circulatory shock is a
frequent and life-threatening condition that needs
prompt and appropriate care.1 With either cardiac
and/or non-cardiac aetiologies, inadequate cardiac
output, altered peripheral vascular tone and/or
loss or imbalance in intravascular volume can con-
tribute to limited delivery anduptake of substrates
in vital organs. If left untreated, hypotension,
hypoperfusion and cellular hypoxia may progress
to organ failure and death.
Fluid resuscitation is a mainstay therapy for the
non-cardiac causes of acute circulatory failure for
patients with sepsis, trauma and burn injury, and
in support of the circulation in critically ill patients
in general. There is a need for clinical practice
guidelines to reflect new evidence concerning the
choice of fluid for therapy of acute circulatory
failure.2 This clinical practice guideline is among
the first to be produced fromour groupmeeting the
new standards for trustworthy guidelines, using
the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) method-
ology (http://www.gradeworkinggroup.org).3–5
Methods
Process
The Clinical Practice Committee of SSAI
appointed national members of the guideline task
force for Acute Circulatory Failure (the authors of
this paper). We invited two colleagues with
focused methodological experience in systematic
reviews and the GRADE system (P. O. V. and M.
H. M.) to help facilitate the work.
The task force identified key clinical questions
for fluid resuscitation, vasopressor therapy, ino-
tropic therapy and diagnostics and monitoring to
fully cover the management of acute circulatory
failure. This is the report of the work on choice of
fluid type for critical care resuscitation.
GRADE
Weused theGRADE system for formulating clinical
questions, assessing the quality of evidence, gener-
ating anticipated absolute effects and for moving
fromevidence to recommendations.5 Briefly, clinical
questions were formulated in a specific format,
which identified the relevant patient population
and/or clinical problem (P), the intervention (I)
under scrutiny as well as the comparator (C), and
patient-important outcomes (O). It is likely that the
efficacy and harm of fluids may be context depen-
dent; that is, they can be different for different
patient populations, comparator fluids and out-
comes. Therefore, we aimed to identify benefits
and harms of crystalloid vs. colloid resuscitation
in critical care by answering the combina-
tion of populations/interventions/comparators/out-
comes (PICO) questions outlined in Table 1
amounting to 12 different specific questions in total.
The populations were general intensive care
unit (ICU) patients, patients with sepsis,
patients with trauma and patients with burn
injury. The standard intervention was crystalloid
solution for resuscitation fluid. Relevant com-
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parators were hydroxyethyl starch (HES), gelatin
or albumin. For the starch solutions, we
assessed when possible HES 130/0.38–0.45
(molecular weight/substitution ratio) rather than
the older products with higher molecular weight
and substitution ratio. The patient outcomes of
interest were mortality, use of renal replacement
therapy (RRT), acute kidney injury (AKI),
bleeding, serious adverse events (SAEs) and
length of hospital stay.
We systematically searched PubMed and the
Cochrane Library for recently updated systematic
reviews of randomised clinical trials (RCTs) com-
paring crystalloid solutionswith colloid solutions.
We updated the searches of the identified reviews
in April 2014 using the search strategies of
these reviews. If we found no systematic review
or subgroup analysis in reviews answering spe-
cific PICOs, as it was the case for patients with
trauma and burn injury, we searched for RCTs in
PubMed [free text: ‘random* and (colloid/HES/
starch/gelatin/albumin) and (trauma/injur*/burn/
thermal)], and in the recently updated systematic
reviews on fluid resuscitation in critically ill
patients in general.2,6–8
The target populations were adult critically ill
patients with acute circulatory failure/shock
resuscitated with crystalloid or colloid in a high-
dependency setting in hospital, including the
emergency department, ICU, operating room or
recovery room. We excluded systematic reviews
and trials done in patients aged less than 18 years,
done in elective surgery, those not comparing
crystalloids with colloids (e.g. colloid vs. colloid)
and those comparing hypertonic crystalloid solu-
tion(s) with colloid. Reviews and trials compar-
ing a crystalloid solution to dextrans or HES with
molecular weight or substitution ratio above 130
or 0.45, respectively, were excluded because these
colloid solutions are less used.9
If we identified trials not included in the sys-
tematic reviews we updated the meta-analyses
with data from the identified RCTs using Revman
5 (http://www.tech.cochrane.org/Revman). If the
identified systematic reviews did not provide rel-
evant meta-analyses for our PICOs, we extracted
data from relevant RCTs and performed meta-
analyses using Revman 5 to obtain pooled effect-
estimates for as many of the PICOs as possible.
In keeping with the GRADE methodology, we
downgraded the quality of evidence for an inter-
vention (our confidence in the effect-estimates)
for identified risks of bias (lack of blinding, or
early termination of studies), inconsistency
(unexplained heterogeneity), indirectness (e.g.
other patient populations or use of surrogate out-
comes), imprecision (wide confidence interval
around the effect estimate) or publication bias (if
identified in the systematic review). The results
were presented in summary of finding tables with
anticipated relative and absolute effects for the
outcomes, together with our confidence in the
effect-estimates using GradePro v. 3.5 (down-
loaded at http://www.gradeworkinggroup.org).
Accordingly, the quality of evidence was rated
from ‘high’ to ‘very low’.
When moving from evidence to recommenda-
tions four factors were considered and integrated:
benefits and harms, quality of evidence, values
and preferences (of patients or their proxies) and
cost considerations. GRADE classifies recommen-
dations as strong when virtually all informed
patients would choose the recommended man-
agement strategy. Weak recommendations, which
Table 1 Clinical and PICO questions used to assess evidence relevant to this guideline statement.
Clinical question
PICO question
Population (P) Intervention (I) Comparator (C) Outcomes (O)
1. Should crystalloid or
colloid solutions be used
for resuscitation of acutely
ill patients with circulatory
failure?
Adult acutely ill patients:
• General ICU patients
• Sepsis
• Trauma
• Burn injury
Crystalloid solutions* Colloid solutions
• HES
• Albumin
• Gelatin
Mortality at longest follow-up
Use of renal replacement therapy
Acute kidney injury
Bleeding
Serious adverse events
Length of hospital stay
*Including isotonic saline or balanced salt solutions including Ringer’s or Hartman’s.
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reflect a close call between benefits and harms,
uncertainty regarding treatment effects, question-
able cost-effectiveness, or variability in values
and preferences, apply when fully informed
patients would choose different management
strategies.5,10
The recommendations were agreed upon by the
group. We specified in advance that if total agree-
ment could not be obtained, the group would
vote; 2/3 of the votes were needed to issue a
strong recommendation. Strong recommenda-
tions were given the wording ‘we recommend’
and weak recommendations ‘we suggest’. If dis-
senting opinions occurred for a specific recom-
mendation, they were included in the text for
clarification.
Results
The results and recommendations based on the
PICOs are presented below, in Table 2 and in the
summary of finding tables given in the Support-
ing information. All members of the guideline
group agreed upon all of the recommendations.
A. Fluid resuscitation of general
ICU patients
1. We recommend that crystalloids are used for
resuscitation in general ICU patients rather than
HES (strong recommendation and moderate
quality of the evidence).
The rationale is that an updated meta-analysis
of crystalloid vs. HES showed clear benefit of
crystalloids when balancing all patient-important
outcomes, including mortality, in critically ill
patients (Table S1A).7 The results are supported
by the meta-analyses comparing HES to any other
comparators2,6 and those of a large, high-quality
RCT that compared 0.9% NaCl with 6%HES 130/
0.4 in 7000 general ICU patients with signs of
hypovolaemia.11 The results of the latter trial indi-
cated no differences in survival or hospital length
of stay between the intervention groups, but the
HES group had increased use of RRT and
increased adverse events, mainly pruritus.
Another recently published large RCT, the
CRISTAL trial,12 compared any crystalloid to any
colloid solution in ICU patients with shock. The
results indicated that colloids (mainly HES) vs.
crystalloids (mainly saline) improved 90-day
mortality, which was a secondary outcome
measure. However, the trial had high risk of bias
in several domains (unblinded, uncertain alloca-
tion concealment and baseline imbalance)13 and
the results differed from those of the high-quality
trials mentioned above. In an accompanying edi-
torial, the editor argued for cautious interpreta-
tion of these findings and that crystalloid should
be the first line fluid in patients with shock.14
Given the high risk of bias in CRISTAL, we did
not take these data into consideration. Based on
the included data we recommend that crystalloid
solutions rather than HES are used for resuscita-
tion in general ICU patients. The binding decision
from European Commission also states that HES
should not be used in critically ill patients.*
2. We suggest that crystalloids are used for
resuscitation in general ICU patients rather than
albumin (weak recommendation and moderate
quality of the evidence).
The rationale is that an updated meta-analysis
of albumin vs. crystalloids in critically ill patients
showed no difference in mortality or in other out-
comes (Table S1B).7 The results are supported by
those of a large, high-quality RCT, the SAFE trial,
which compared 0.9% NaCl with 4% albumin in
7000 general ICU patients with signs of hypovo-
laemia.15 In that trial none of the outcome mea-
sures differed between the two intervention
groups, including mortality, use of RRT and hos-
pital length of stay (Table S1B). No cost minimi-
sation analysis was made in SAFE, but albumin is
a blood product and as such a limited resource
and its cost is much higher than that of crystal-
loids. Therefore, we suggest using the latter in
general ICU patients.
3. We suggest that crystalloids are used for
resuscitation in general ICU patients rather than
gelatin (weak recommendation and very low
quality of the evidence).
The rationale is that the updated meta-analysis
of gelatin vs. crystalloids in critically ill patients
showed no difference in mortality (Table S1C).7
However, there were few events in the trials
included and the pooled effect-estimate was
imprecise. Therefore the benefits and harms of
gelatin are largely unknown in these patients, but
they have been associated with increased risk of
AKI and bleeding.16,17 These observations are
*http://www.ec.europa.eu/health/documents/community-register/
2013/20131219127286/dec_127286_en.pdf
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Table 2 Key recommendations and quality of evidence.
Strength of the
recommendation Benefits and harms
Quality of
evidence
Reason(s) for
downgrading Comments
Fluid resuscitation of general ICU patients
1. We recommend that
crystalloids are used for
resuscitation in general ICU
patients rather than HES
Strong An updated meta-analysis of
crystalloid vs. HES in critically ill
patients showed clear beneﬁt
of crystalloids when balancing
all patient-important outcomes,
including mortality
Moderate due to
risk of bias
2. We suggest that
crystalloids are used for
resuscitation in general ICU
patients rather than
albumin
Weak An updated meta-analysis of
crystalloids vs. albumin in
critically ill patients showed no
difference in mortality or in
other important outcomes
Moderate due to
risk of bias
Albumin is a blood product
and a limited and costly
resource
3. We suggest that
crystalloids are used for
resuscitation in general ICU
patients rather than gelatin
Weak An updated meta-analysis of
crystalloids vs. gelatin in
critically ill patients showed no
difference in mortality
Very low due to
risk of bias and
imprecision
Beneﬁts and harms of gelatin
are largely unknown, but
they have been associated
with increased risk of acute
kidney injury and bleeding
in observational studies
Fluid resuscitation of patients with sepsis
1. We recommend that
crystalloids are used for
resuscitation in patients
with sepsis rather than
HES.
Strong In two recently updated
systematic meta-analyses of
crystalloid vs. HES in critically ill
septic patients, HES increased
long-term (> 28 days) mortality,
use of RRT and rates SAEs
compared to crystalloids
Moderate due to
imprecision
2. We suggest that
crystalloids are used for
resuscitation in patients
with sepsis rather than
albumin.
Weak A meta-analysis of data from the
SAFE and ALBIOS trials showed
no beneﬁt or harm from
albumin compared to saline
Low due to risk of
bias
Albumin is a blood product
and a limited and costly
resource
3. We suggest that
crystalloids are used for
resuscitation in patients
with sepsis rather than
gelatin.
Weak No meta-analyses or RCTs exist of
crystalloids vs. gelatin in
patients with sepsis
Very low due to
lack of RCTs and
meta-analyses
Beneﬁts and harms of gelatin
are largely unknown, and
they have been associated
with increased risk of acute
kidney injury and bleeding
in observational studies
Fluid resuscitation of patients with trauma
We recommend that
crystalloids are used for
resuscitation in patients
with trauma rather than
colloids.
Strong A meta-analysis of data of existing
RCTs in patients with trauma
showed that colloid
resuscitation was associated
with increased risk of death
Very low due to
risk of bias and
imprecision
Fluid resuscitation of patients with burn
No recommendation Very limited data from RCTs Very low due to
risk of bias and
imprecision
We refrain from giving any
recommendations because
of the very low level of
evidence
A. PERNER ET AL.
Acta Anaesthesiologica Scandinavica 59 (2015) 274–285
© 2014 The Authors. The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd278
supported by data from an updated meta-analysis
of gelatin vs. albumin/crystalloid.18 As mentioned
above, there appears to be no benefit of other
colloid solutions in critically ill patients in
general, and therefore we suggest that gelatin is
not used in these patients. However, the quality of
the evidence is very low for this suggestion.
B. Fluid resuscitation of patients with sepsis
1. We recommend that crystalloids are used for
resuscitation in patients with sepsis rather than
HES (strong recommendation and moderate
quality of the evidence).
The rationale is based on two recently updated
systematic reviews on patients with sepsis,19,20
which included most of the same RCTs (we chose
to use data from the one including most trials –
nine trials with 3456 patients also including SAEs
as an outcome vs. six trials with 3033 patients)
(Table S2A). The systematic review we report
included twoRCTs that used albumin as compara-
tor,19 however few patients received albumin and
these contributed with few events and only in the
outcomes mortality and SAEs. There was overall
heterogeneity among trial results, but this was
balanced by the pre-defined subgroup analysis of
trials with low risk of bias. These trials also had
follow-up for mortality for more than 28 days,
which is important because the difference in mor-
tality between patients assigned to HES vs. crys-
talloid was observed beyond day 28 in one trial.21
In patients with sepsis, HES 130/0.38–0.45
increased long-term (> 28 days) mortality com-
pared to crystalloids (Table S2A). In addition, the
use of RRT was increased and more patients had
SAEs with HES compared to crystalloids
(Table S2A). The binding decision from the Euro-
pean Commission also states that HES should not
be used in patients with sepsis.*
2. We suggest that crystalloids are used for
resuscitation in patients with sepsis rather than
albumin (weak recommendation and moderate
quality of the evidence).
We identified a recently updated systematic
review including 17 RCTs.22 In 12 of the trials
included in that review, the comparator was a syn-
thetic colloid, three trials were in children, and one
in ARDS patients. As the SAFE trial was the only
RCTcomparingalbumin to crystalloid that included
adults with sepsis, we base our suggestion on data
from SAFE15 and the recently published ALBIOS
trial.23 In SAFE, the 1218 included patients with
severe sepsis were analysed as predefined sub-
group, but sepsis was not a stratification variable at
randomisation. In the subgroup analysis of these
patients there was a trend towards lower 28-day
mortality with albumin vs. saline. In the ALBIOS
trial, 1818 patients with severe sepsis were ran-
domised to 20% albumin vs. saline, but there were
no differences in 28-day mortality, which was the
primary outcome, or in any of the secondary
outcome measures.23 Pooling the data from the
SAFEandALBIOS trials showednobenefit or harm
from albumin compared with saline (Fig. 1 and
Table S2B). Economic analyses were not made in
SAFE or ALBIOS, but albumin is a limited and
costly resource. Emerging data from RCTs in adults
with sepsiswill hopefully clarify the indications for
albumin. Until then we suggest not to use albumin
for resuscitation in adults with sepsis.
3. We suggest that crystalloids are used for
resuscitation in patients with sepsis rather than
gelatin (weak recommendation and very low
quality of the evidence).
The rationale is based on a recently updated
systematic review where no RCTs could be
included for adult patients with sepsis.18 We have
updated the search and also found no RCTs in
adult patients with sepsis comparing gelatin to
crystalloids. Therefore the benefits and harms of
gelatin are unknown in patients with sepsis. As
noted above, gelatin has been associated with
increased risk of kidney failure and bleeding.16,17
The results from trials assessing other colloids
indicate that there are little, if any, differences in
fluid volumes and circulatory parameters
between patients with sepsis resuscitated with
colloid vs. crystalloid solutions.21,24 Therefore, we
recommend that if clinicians want to use gelatin
in sepsis, this should only be in the context of an
RCT of sufficient size to detect side effects, a
notion supported by the European Society of
Intensive Care Medicine task force on colloids.25
C. Fluid resuscitation of patients
with trauma
1. We recommend that crystalloids are used for
resuscitation in patients with trauma rather than
colloids (strong recommendation and low quality
of the evidence).
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We did not identify an updated systematic
review of patients with trauma. In the updated,
large systematic reviews of critically ill patients
we found RCTs examining crystalloid vs. colloid
solutions in trauma. Our own meta-analysis of
data of the RCTs in patients with trauma showed
that colloid resuscitation was associated with an
increased risk of death [Fig. 2 and (Table S3A–
C)]. There were not sufficient data to analyse the
other outcome measures.
D. Fluid resuscitation of patients with
burn injury
For patients with burn injury we could not find
updated systematic reviews and we only identi-
fied three small RCTs that were relevant for this
clinical question.26–28 Two of these trials were on
albumin vs. Ringer’s lactate and both were small
(total n = 79 and n = 42) and the larger trial had
high risk of bias (lack of allocation concealment
and blinding).26 The third trial assessed 48
patients randomised to HES 130/0.40 vs. Ringer’s
lactate and showed no benefit or harm of HES,28
but the interpretation is hampered by the small
sample size (imprecision). Based on the very
limited amount of data (Fig. 3 and Table S4A–C)
we refrain from giving any recommendations or
suggestions on choice of resuscitation fluid for
burn patients. However, we strongly recommend
that clinicians who continue to use colloid solu-
tions in patients with burn injury do so in the
context of high quality RCTs given the limited
effects and harms observed with colloids in other
patient groups (ungraded). And clinicians should
be aware of the binding decision from the Euro-
pean Commission, which states that HES should
not be used in patients with burn injury.*
Discussion
This guideline on fluid resuscitation has been
produced following the recently, updated, high-
quality meta-analyses comparing crystalloids
with colloids.2,6,7,19 In addition we meta-analysed
data from RCTs in several patient groups to obtain
a base for moving from evidence to recommenda-
tions or suggestions for as many of the PICO
questions as possible. We have issued several
strong recommendations favouring crystalloids
over colloids in all patient groups. This was based
on overall low confidence of benefit from colloid
resuscitation, confidence of harm caused by the
synthetic colloids (high confidence for HES and
low for gelatin) and high cost of albumin, which
is also a limited resource. For patients with burn
Fig. 1. Forest plot of (A) all-cause mortality and (B) renal replacement therapy in randomised trials of crystalloid vs. albumin for resuscitation of
patients with sepsis. Size of squares for risk ratio reﬂects weight of trial in pooled analyses. Horizontal bars represent 95% conﬁdence intervals.
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injury, we considered the quality of the evidence
to be very low and chose not to issue recommen-
dations for these patients. Patients with burn
injury likely represent a specific entity because of
the massive capillary leak and therefore the
results from the other patient categories may be
less applicable to these patients. It is our impres-
sion that colloid solutions, albumin in particular,
are part of burn resuscitation in clinical practice.
Therefore, high-quality trials are urgently needed
in patients with burn injury to ensure that this
practice is cost-effective and without harm. The
use of HES, on the other hand, is now restricted in
patients with burn injury by EU legislation.
Our recommendation against the three types of
colloids, albumin, HES and gelatin, may result in
increased use of dextrans29,30 or the development
of new types of colloids. We believe that clini-
cians who would consider using dextrans or other
types of colloids should do so only in the context
of RCTs. The likelihood that dextrans or other
colloids would benefit critically ill patients is low
given the lack of benefit of albumin. In addition
the risk of harm by dextrans, in particular, is
eminent because they have been associated with
AKI and bleeding.31,32
The strengths of our guideline include the
application of new standards for trustworthy
guidelines and the use of the GRADE methodol-
ogy, which ensured a systematic and transparent
process. The limitations include the reliance upon
recently updated systematic reviews for the
majority of recommendations. In these, there was
no subgrouping of patients based on indications
for fluid therapy, most likely because no single
indications are supported by high-quality data.
Fig. 2. Forest plot of all-cause mortality in randomised trials of crystalloid vs. colloid solutions for resuscitation of patients with trauma.11,15,34–39 The
trial results were sub-grouped based on the colloid solution (albumin, starch and gelatin) used in the trials. Size of squares for risk ratio reﬂects
weight of trial in pooled analyses. Horizontal bars represent 95% conﬁdence intervals.
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We did several meta-analyses, but the number of
included RCTs was small, which is a limitation in
the evidence base not the guideline per se. We did
not include all patient-important outcome mea-
sures (e.g. quality of life), because we, a priori,
found it less likely to find data from meta-
analyses or RCTs on these outcomes. To our
knowledge there is only one report on data on
quality of life of patients randomised to different
types of fluids.33 Bias may have influenced the
results as the chair of the task force was the prin-
cipal investigator of the 6S trial,21 which showed
harm from HES in sepsis. However, all members
of the group formed and agreed upon all recom-
mendations and suggestions in this guideline,
making it less likely that bias influenced the
results and recommendations.
In conclusion, we recommend using crystal-
loids for resuscitation of critically ill adult
patients including general ICU patients and those
with sepsis or trauma. We refrain from giving any
recommendations or suggestions on choice of
resuscitation fluid for patients with burn injury,
because of the very low quality of evidence in
these patients. If resuscitation using colloids is to
continue, high-quality trials should be performed
to ensure patient safety and overall benefit for
patients and society.
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Supporting information
Additional Supporting Information may be found
in the online version of this article at the publish-
er’s web-site:
Table S1. (A) Question: Should crystalloids or
HES be used for acute circulatory failure in
general ICU patients? (B) Question: Should crys-
talloids or albumin be used for acute circulatory
failure in general ICU patients? (C) Question:
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Should crystalloids or gelatin be used for acute
circulatory failure in general ICU patients?
Table S2. (A) Question: Should crystalloids or
HES be used for acute circulatory failure in
patients with sepsis? (B) Question: Should crys-
talloids or albumin be used for acute circulatory
failure in patients with sepsis? (C) Question:
Should crystalloids or gelatin be used for acute
circulatory failure in patients with sepsis?
Table S3. (A) Question: Should crystalloids or
HES be used for acute circulatory failure in
patients with trauma? (B) Question: Should crys-
talloids or albumin be used for acute circulatory
failure in patients with trauma? (C) Question:
Should crystalloids or gelatin be used for acute
circulatory failure in patients with trauma?
Table S4. (A) Question: Should crystalloids or
HES be used for acute circulatory failure in
patients with burn? (B) Question: Should crystal-
loids or albumin be used for acute circulatory
failure in patients with burn? (C) Question:
Should crystalloids or gelatin be used for acute
circulatory failure in patients with burn?
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